Disease · MONDO_0019434
systemic-onset juvenile idiopathic arthritis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. systemic-onset juvenile idiopathic arthritis. Diseases, record MONDO_0019434. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019434
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- SoJIA, Still disease, sJIA, systemic juvenile idiopathic arthritis, systemic polyarthritis, systemic-onset JIA
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CANAKINUMAB | CHEMBL1201834 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TOFACITINIB | CHEMBL221959 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RILONACEPT | CHEMBL1201830 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EMAPALUMAB | CHEMBL3989977 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GIVINOSTAT | CHEMBL1213492 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAS-825 | CHEMBL5315029 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| JAK1 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| IL1B | Interleukin-1 beta | 2 | Interleukin-1 beta inhibitor | Phase 3 | https://conductscience.org/library/genes/3553 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 2 | Interleukin-6 receptor alpha subunit antagonist; Interleukin-6 receptor alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 3 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| HDAC1 | Histone deacetylase | 1 | Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/3065 | Drugs and targets |
| HDAC10 | Histone deacetylase | 1 | Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/83933 | Drugs and targets |
| HDAC11 | Histone deacetylase | 1 | Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/79885 | Drugs and targets |
| HDAC2 | Histone deacetylase | 1 | Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/3066 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials27
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00891046 | An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. | Phase 3 | 270 | 2017-03-10 | Systemic Juvenile Idiopathic Arthritis | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02592434 | Efficacy Study Of Tofacitinib In Pediatric JIA Population | Phase 3 | 225 | 2020-02-21 | Juvenile Idiopathic Arthritis | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02296424 | ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab | Phase 3 | 182 | 2019-07-09 | Systemic Juvenile Idiopathic Arthritis (SJIA) | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00889863 | Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | Phase 3 | 177 | 2012-10-16 | Systemic Juvenile Idiopathic Arthritis With Active Flare | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03000439 | A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA | Phase 3 | 100 | 2025-06-03 | Arthritis Juvenile Idiopathic | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00886769 | Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) | Phase 3 | 84 | 2012-04-09 | Systemic Juvenile Idiopathic Arthritis | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00534495 | Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults | Phase 2 | 71 | 2015-12-11 | Juvenile Idiopathic Arthritis | RILONACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT02334748 | A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies | Phase 3 | 31 | 2020-05-19 | Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02396212 | Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA | Phase 3 | 19 | 2019-09-13 | Systemic Juvenile Idiopathic Arthritis | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00570661 | Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis | Phase 2 | 17 | 2021-05-04 | Active Systemic, Onset Juvenile Idiopathic Arthritis | GIVINOSTAT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 27
See all 27 trialsComparisons in its trials31
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ACZ885 Treatment Naive vs ACZ885 Treated: Number of Participants With Anti -ACZ885 Antibodies at Any Visit During the Study | 0 of 123 | 0 of 147 | 270 | NCT00891046 | Trial comparisons |
| ACZ885 Treated vs ACZ885 Treatment Naive: serious adverse events | 47 of 147 | 40 of 123 | 270 | NCT00891046 | Trial comparisons |
| Canakinumab vs Placebo: serious adverse events | 2 of 43 | 2 of 41 | 84 | NCT00886769 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Macrophage Activation Syndrome (MAS). | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra. | 6 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Neutralizing Antibodies. | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With at Least One Serious Adverse Event Including Death. | 0 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With at Least One Adverse Event. | 6 of 6 | 4 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: deaths from any cause | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: serious adverse events | 0 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
1 to 10 of 31
See all 31 comparisons in its trialsPapers from its trials21
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 40312101 | DERIVED | 1 | PubMed |
| 38662147 | DERIVED | 1 | PubMed |
| 38552315 | DERIVED | 1 | PubMed |
| 38298058 | DERIVED | 1 | PubMed |
| 37001971 | DERIVED | 1 | PubMed |
| 35105709 | DERIVED | 1 | PubMed |
| 34767764 | DERIVED | 1 | PubMed |
| 33506875 | DERIVED | 1 | PubMed |
| 32783351 | DERIVED | 1 | PubMed |
| 32552266 | DERIVED | 1 | PubMed |
1 to 10 of 21
See all 21 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019434
GET https://conductscience.org/api/diseases/v1/MONDO_0019434/trials?page=2